Hosted on MSN19h
SGLT1/2 Inhibitor Cut Stroke, Heart Attack Risk in Diabetic Kidney Disease
The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...
2 Healthcare Stocks That Tumbled in 2024...but Could See an Impressive Comeback in 2025
In a phase 2 study, the company's medication suzetrigine barely performed better than a placebo in treating painful ...
AstraZeneca (LON:AZN) Stock Crosses Above 200 Day Moving Average – Time to Sell?
AstraZeneca PLC (LON:AZN – Get Free Report) shares passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of £114.82 ($144.52) and traded as high as ...
You can cash in with Britain's £78BN rival to Silicon Valley
Chancellor Rachel Reeves is hoping the sun will shine on a 66-mile strip between Britain's top two universities which she ...
The American Journal of Managed Care8h
Pursuit of ADCs in Bladder Cancer Comes With Questions About Toxicity, Cost
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...
Hosted on MSN17h
Today-History-Feb15
Today in History for Feb. 15: ...